These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29120250)

  • 1. Retinal Vascular Caliber Changes After Topical Nepafenac Treatment for Diabetic Macular Edema.
    Evliyaoğlu F; Akpolat Ç; Kurt MM; Çekiç O; Nuri Elçioğlu M
    Curr Eye Res; 2018 Mar; 43(3):357-361. PubMed ID: 29120250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical nepafenec in eyes with noncentral diabetic macular edema.
    Friedman SM; Almukhtar TH; Baker CW; Glassman AR; Elman MJ; Bressler NM; Maker MP; Jampol LM; Melia M;
    Retina; 2015 May; 35(5):944-56. PubMed ID: 25602634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
    Tzelikis PF; Morato CS; Neves NT; Hida WT; Alves MR
    J Cataract Refract Surg; 2018 Apr; 44(4):440-446. PubMed ID: 29685777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.
    Warren KA; Fox JE
    Retina; 2008; 28(10):1427-34. PubMed ID: 18664937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema.
    Wickremasinghe SS; Rogers SL; Gillies MC; Zhu M; Wong TY
    Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4707-11. PubMed ID: 18599569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
    Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ
    Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo.
    McCafferty S; Harris A; Kew C; Kassm T; Lane L; Levine J; Raven M
    BMC Ophthalmol; 2017 Feb; 17(1):16. PubMed ID: 28219426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of macular edema after cataract surgery in diabetic patients, topical Nepafenac versus intravitreal Ranibizumab.
    Howaidy A; Eldaly ZH; Anis M; Othman TM
    Eur J Ophthalmol; 2022 Jan; 32(1):205-212. PubMed ID: 33726537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Subtenon Triamcinolone Acetonide Injection with Topical Nepafenac for the Treatment of Pseudophakic Cystoid Macular Edema.
    Yüksel B; Uzunel UD; Kerci SG; Sağban L; Küsbeci T; Örsel T
    Ocul Immunol Inflamm; 2017 Aug; 25(4):513-519. PubMed ID: 27015572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
    Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
    Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac.
    Sengupta S; Vasavada D; Pan U; Sindal M
    Indian J Ophthalmol; 2018 Jun; 66(6):827-830. PubMed ID: 29785993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial.
    Campa C; Salsini G; Perri P
    Curr Eye Res; 2018 Mar; 43(3):362-367. PubMed ID: 29120255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Topical Non-steroidal Anti-inflammatory Drugs for Uveitic Cystoid Macular Edema.
    Petrushkin H; Rogers D; Pavesio C
    Ocul Immunol Inflamm; 2018; 26(5):795-797. PubMed ID: 28080174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery.
    Naithani P; Puranik S; Vashisht N; Khanduja S; Kumar S; Garg S
    Retina; 2012 Feb; 32(2):250-5. PubMed ID: 21926942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.
    Miyake K; Ota I; Miyake G; Numaga J
    J Cataract Refract Surg; 2011 Sep; 37(9):1581-8. PubMed ID: 21855758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystoid and diabetic macular edema treated with nepafenac 0.1%.
    Hariprasad SM; Callanan D; Gainey S; He YG; Warren K
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):585-90. PubMed ID: 18001248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
    Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
    Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative management in cataract surgery: nepafenac and preservative-free diclofenac compared.
    Ylinen P; Taipale C; Lindholm JM; Laine I; Holmström E; Tuuminen R
    Acta Ophthalmol; 2018 Dec; 96(8):853-859. PubMed ID: 30284393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.